Author

Georg Semmler

SAFETY OF DIRECT ORAL ANTICOAGULANTS (DOACS) IN PATIENTS WITH ADVANCED LIVER DISEASE
SAFETY OF DIRECT ORAL ANTICOAGULANTS (DOACS) IN PATIENTS WITH ADVANCED LIVER DISEASE

Georg Semmler  et al.

DISTURBANCES IN SODIUM AND CHLORIDE HOMEOSTASIS PREDICT OUTCOMES IN STABLE AND CRITICALLY ILL PATIENTS WITH CIRRHOSIS – NOT TWO SIDES OF THE SAME COIN
DISTURBANCES IN SODIUM AND CHLORIDE HOMEOSTASIS PREDICT OUTCOMES IN STABLE AND CRITICALLY ILL PATIENTS WITH CIRRHOSIS – NOT TWO SIDES OF THE SAME COIN

GASTROENTEROLOGIST AGAINST THE MACHINE – OPPORTUNITIES AND LIMITATIONS OF MACHINE LEARNING FOR PREDICTION OF ADVANCED ADENOMA
GASTROENTEROLOGIST AGAINST THE MACHINE – OPPORTUNITIES AND LIMITATIONS OF MACHINE LEARNING FOR PREDICTION OF ADVANCED ADENOMA

Georg Semmler  et al.

PROGNOSTIC UTILITY OF THE BAVENO VII CRITERIA FOR A CLINICALLY SIGNIFICANT DECREASE IN LIVER STIFFNESS MEASUREMENT AFTER HCV-CURE
PROGNOSTIC UTILITY OF THE BAVENO VII CRITERIA FOR A CLINICALLY SIGNIFICANT DECREASE IN LIVER STIFFNESS MEASUREMENT AFTER HCV-CURE

Georg Semmler  et al.

PERIPORTAL HYPERINTENSITY FACILITATES DIAGNOSIS OF PORTO-SINUSOIDAL VASCULAR DISORDER
PERIPORTAL HYPERINTENSITY FACILITATES DIAGNOSIS OF PORTO-SINUSOIDAL VASCULAR DISORDER

Georg Semmler  et al.

THE RISKS OF FIRST HEPATIC DECOMPENSATION AND HCC REMAIN CONSTANT DURING LONG-TERM FOLLOW-UP AND CAN BE STRATIFIED BY A ONE-TIME ASSESSMENT AFTER HCV-CURE
THE RISKS OF FIRST HEPATIC DECOMPENSATION AND HCC REMAIN CONSTANT DURING LONG-TERM FOLLOW-UP AND CAN BE STRATIFIED BY A ONE-TIME ASSESSMENT AFTER HCV-CURE

Georg Semmler  et al.

VALIDATION AND REFINEMENT OF THE BAVENO VII CRITERIA FOR RISK STRATIFICATION IN COMPENSATED ADVANCED CHRONIC LIVER DISEASE AFTER HCV-CURE
VALIDATION AND REFINEMENT OF THE BAVENO VII CRITERIA FOR RISK STRATIFICATION IN COMPENSATED ADVANCED CHRONIC LIVER DISEASE AFTER HCV-CURE

Georg Semmler  et al.

DIRECT ORAL ANTICOAGULANTS (DOACS) FOR OFF-LABEL USE IN PATIENTS WITH BUDD CHIARI SYNDROME (BCS)
DIRECT ORAL ANTICOAGULANTS (DOACS) FOR OFF-LABEL USE IN PATIENTS WITH BUDD CHIARI SYNDROME (BCS)

Georg Semmler  et al.

SAFETY OF DIRECT ORAL ANTICOAGULANTS (DOACS) IN PATIENTS WITH ADVANCED LIVER DISEASE
SAFETY OF DIRECT ORAL ANTICOAGULANTS (DOACS) IN PATIENTS WITH ADVANCED LIVER DISEASE

DIRECT ORAL ANTICOAGULANTS (DOACS) FOR OFF-LABEL USE IN PATIENTS WITH BUDD CHIARI SYNDROME (BCS)
DIRECT ORAL ANTICOAGULANTS (DOACS) FOR OFF-LABEL USE IN PATIENTS WITH BUDD CHIARI SYNDROME (BCS)

NON-INVASIVE TESTS FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AFTER HCV-CURE – INDIVIDUAL PATIENT DATA META-ANALYSIS AND VALIDATION
NON-INVASIVE TESTS FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AFTER HCV-CURE – INDIVIDUAL PATIENT DATA META-ANALYSIS AND VALIDATION

Georg Semmler  et al.

PERIPORTAL HYPERINTENSITY FACILITATES DIAGNOSIS OF PORTO-SINUSOIDAL VASCULAR DISORDER
PERIPORTAL HYPERINTENSITY FACILITATES DIAGNOSIS OF PORTO-SINUSOIDAL VASCULAR DISORDER

METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD) – RATHER A BYSTANDER THAN A DRIVER OF MORTALITY
METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD) – RATHER A BYSTANDER THAN A DRIVER OF MORTALITY

Georg Semmler  et al.

GASTROENTEROLOGIST AGAINST THE MACHINE - OPPORTUNITIES AND LIMITATIONS OF MACHINE LEARNING FOR PREDICTION OF ADVANCED ADENOMA
GASTROENTEROLOGIST AGAINST THE MACHINE - OPPORTUNITIES AND LIMITATIONS OF MACHINE LEARNING FOR PREDICTION OF ADVANCED ADENOMA

NON-INVASIVE TESTS FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AFTER HCV-CURE – INDIVIDUAL PATIENT DATA META-ANALYSIS AND VALIDATION
NON-INVASIVE TESTS FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AFTER HCV-CURE – INDIVIDUAL PATIENT DATA META-ANALYSIS AND VALIDATION

DISTURBANCES IN SODIUM AND CHLORIDE HOMEOSTASIS PREDICT OUTCOMES IN STABLE AND CRITICALLY ILL PATIENTS WITH CIRRHOSIS – NOT TWO SIDES OF THE SAME COIN
DISTURBANCES IN SODIUM AND CHLORIDE HOMEOSTASIS PREDICT OUTCOMES IN STABLE AND CRITICALLY ILL PATIENTS WITH CIRRHOSIS – NOT TWO SIDES OF THE SAME COIN

Georg Semmler  et al.

SAFETY OF DIRECT ORAL ANTICOAGULANTS (DOACS) IN PATIENTS WITH ADVANCED LIVER DISEASE
SAFETY OF DIRECT ORAL ANTICOAGULANTS (DOACS) IN PATIENTS WITH ADVANCED LIVER DISEASE

Georg Semmler

METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD) - RATHER A BYSTANDER THAN A DRIVER OF MORTALITY
METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD) - RATHER A BYSTANDER THAN A DRIVER OF MORTALITY

A FIB-4/VITRO SEQUENCE ALLOWS FOR DIAGNOSIS OF COMPENSATED ADVANCED CHRONIC LIVER DISEASE AND RISK STRATIFICATION FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION
A FIB-4/VITRO SEQUENCE ALLOWS FOR DIAGNOSIS OF COMPENSATED ADVANCED CHRONIC LIVER DISEASE AND RISK STRATIFICATION FOR CLINICALLY SIGNIFICANT PORTAL HYPERTENSION

Georg Semmler  et al.

CLINICAL COURSE OF FURTHER DECOMPENSATION/MORTALITY IN PATIENTS WITH CIRRHOSIS AND ASCITES AS THE FIRST SINGLE DECOMPENSATION EVENT – AN INCEPTION COHORT STUDY
CLINICAL COURSE OF FURTHER DECOMPENSATION/MORTALITY IN PATIENTS WITH CIRRHOSIS AND ASCITES AS THE FIRST SINGLE DECOMPENSATION EVENT – AN INCEPTION COHORT STUDY

Georg Semmler  et al.

Item 1 - 20 / 32
1
2